Production (Stage)
CytomX Therapeutics, Inc.
CTMX
$2.75
-$0.24-8.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 50.92M | 38.09M | 33.43M | 25.12M | 41.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 50.92M | 38.09M | 33.43M | 25.12M | 41.46M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 50.92M | 38.09M | 33.43M | 25.12M | 41.46M |
| SG&A Expenses | 9.43M | 5.62M | 7.95M | 8.40M | 7.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.30M | 20.41M | 29.32M | 33.57M | 29.81M |
| Operating Income | 22.62M | 17.68M | 4.11M | -8.45M | 11.66M |
| Income Before Tax | 23.59M | 18.94M | 5.80M | -6.48M | 13.84M |
| Income Tax Expenses | 62.00K | 62.00K | 61.00K | 51.00K | 49.00K |
| Earnings from Continuing Operations | 23.53M | 18.88M | 5.74M | -6.53M | 13.79M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.53M | 18.88M | 5.74M | -6.53M | 13.79M |
| EBIT | 22.62M | 17.68M | 4.11M | -8.45M | 11.66M |
| EBITDA | 23.01M | 18.09M | 4.54M | -7.99M | 12.12M |
| EPS Basic | 0.27 | 0.22 | 0.07 | -0.08 | 0.17 |
| Normalized Basic EPS | 0.17 | 0.14 | 0.04 | -0.05 | 0.11 |
| EPS Diluted | 0.27 | 0.22 | 0.07 | -0.08 | 0.17 |
| Normalized Diluted EPS | 0.17 | 0.14 | 0.04 | -0.05 | 0.10 |
| Average Basic Shares Outstanding | 87.12M | 85.74M | 85.09M | 84.88M | 82.03M |
| Average Diluted Shares Outstanding | 87.15M | 85.74M | 85.20M | 84.88M | 82.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |